The REFINE Trial is presented at the European Society for Medical Oncology Congress
20 Sep 2022
Sophie Merrick presented the REFINE trial at the European Society for Medical Oncology (ESMO) Congress in Paris on the 12th September.
The REFINE trial is testing different time intervals of treatment using checkpoint inhibitors, to treat different types of cancers (renal, melanoma and colorectal).
The REFINE renal cancer cohort opened to recruitment on the 25th May 2022 and we plan to open the melanoma cohort next.
REFINE is a multi-stage trial. In stage I, each cohort aims to recruit 160 participants. Once this target is reached, an interim analysis of progression-free survival will be completed. This will determine if recruitment should continue to 360 participants, which will then start stage II.
REFINE is recruiting across multiple sites in the UK and is funded by the Jon Moulton Charity Trust and Medical Research Council.
There will also be a translational Sub-study that will look at blood and biopsy samples to understand the patient's response to the treatment. This Sub-study will be funded by the Cancer Research UK.
A pdf copy of the poster can be downloaded here.
Further information: